Purchase this article with an account.
M. R. Paterno, L. S. Brunner, S. E. Norton, J. M. Blondeau; In vitro Activity of SS734, a Novel Fluoroquinolone for Bacterial Conjunctivitis, Against Ocular Isolates From a Phase II Clinical Study. Invest. Ophthalmol. Vis. Sci. 2007;48(13):766.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
SS734 is a novel fluoroquinolone being investigated for the treatment of bacterial conjunctivitis. The objective of this study was to determine the in vitro activity of SS734 against ocular isolates from a Phase II safety and efficacy study.
Minimum inhibitory concentrations (MICs) were determined according to the recommended procedure of the Clinical and Laboratory Standards Institute by broth microdilution: Briefly, approximately 105 CFU/ml were exposed to doubling dilutions of drug and following incubation in the appropriate atmosphere and temperature for 18-24 hours, the lowest concentration preventing growth was the MIC.
A total of 35 species of ocular pathogens were identified. The MICs of SS734 against pathogens with more than 10 clinical isolates were as follows:
SS734, a novel fluoroquinolone, is highly active in vitro against Phase II ocular isolates of H. influenzae, S. pneumoniae, S. aureus and S. epidermidis with MICs well below the expected drug concentrations delivered to the eye during therapy. Based on these in vitro observations, SS734 appears to be a promising new agent for further clinical investigation for the treatment of bacterial conjunctivitis.
This PDF is available to Subscribers Only